An experimental drug from Merck & Co. raised levels of good cholesterol, slashed bad cholesterol and may have helped patients avert heart complications, without the safety risks that prompted Pfizer Inc. to abandon a similar product four years ago.
http://www.chron.com/disp/story.mpl/business/7299042.html
http://www.chron.com/disp/story.mpl/business/7299042.html